Please ensure Javascript is enabled for purposes of website accessibility

Abiomed Pumps Out Triple-Digit Profit Growth and Boosts Guidance (Again)

By Brian Feroldi - Nov 2, 2018 at 2:55PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Demand for the company's Impella family of temporary heart pumps remains as robust as ever.

Medical device maker Abiomed (ABMD 0.24%) reported its fiscal second-quarter results on Thursday. Revenue growth came in at a healthy 37% thanks to increased penetration rates in the U.S. and a continued push into the rest of the world. Operating leverage helped translate the strong top-line growth into another triple-digit gain on the bottom line.

Abiomed's fiscal second quarter: The raw numbers


Q2 2019

Q2 2018

Year-Over-Year Change


$181.8 million

$132.8 million


GAAP net income

$50.1 million

$24.5 million


Earnings per share




Data source: Abiomed.

What happened with Abiomed this quarter?

  • Sales in the U.S. grew at a 34% clip. The rate of growth outside the states was even more impressive at 67%.
  • Revenue from Japan totaled $4.1 million. A total of 14 sites are now up and running.
  • Gross margin remained very strong at 83.6%.
  • Impella reorder rates remain around 100%.
  • Operating margin for the period was 27.7%. That was a 380-basis-point increase over the same time last year.
  • Net income was boosted by a $12.9 million tax gain, or $0.28 per share.
  • Cash balance at quarter end was $410 million. The balance sheet remains free of debt.
Surgeon with gloves on

Image source: Getty Images.

What management had to say

CEO Michael Minogue was quite pleased with his company's performance during the quarter: "We have established a strong foundation with our innovation and technology, balance sheet, and intellectual-property portfolio. We are executing our plan for sustainable growth, while helping to improve patient outcomes focused on native-heart recovery."

Minogue also stated that the company only recently surpassed a 10% penetration rate in the U.S., which reaffirms that the business still has a huge runway for growth ahead.

Looking forward

Abiomed announced that data from its STEMI (ST-segment elevation myocardial infarction) DTU (door-to-unloading) safety and feasibility study, approved by the Food and Drug Administration, will be released at the upcoming American Heart Association's Scientific Sessions on Nov. 11. The company plans on holding a short call with investors the following day to discuss the results in more detail.

For the second time this fiscal year, CFO Todd Trapp boosted the low end of full-year revenue guidance. The new range calls for revenue to land between $765 million and $770 million, which implies year-over-year growth of 29% to 30%. The company also reaffirmed its goal of a delivering a GAAP (generally accepted accounting principles) operating margin in 2019 in the range of 28% to 30%.

Trapp also stated that Abiomed expects to show "solid growth" in the back half of the fiscal year, as it laps challenging year-over-year comparisons.

During his final remarks on the conference call with investors, Minogue reaffirmed that the company is well-positioned to drive continued growth:

We are confident in our future, with Impella growth opportunities of several hundred thousand patients with new and existing indications, new products, and new geographies. No other company provides approved percutaneous heart pumps that unload the left and right ventricle, and protect and recover heart muscle for elective, urgent, and emergent patients. I am proud of our employees and appreciate their dedication to recovering hearts and saving lives, and I'm thankful to our customers and our shareholders for their continued support.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ABIOMED, Inc. Stock Quote
$255.18 (0.24%) $0.62

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/05/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.